HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

MDSO: Medidata Solutions Inc - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
MEDIDATA SOLUTIONS INC (NASD)
MDSO 16.68 -1.10 (-6.19%) Vol.  143,971 16:00 ET
Medidata Solutions is a leading global provider of hosted clinical development solutions that enhance the efficiency of customers' clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer), investigator benchmarking and budgeting (Medidata Grants Manager), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave). Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes some top global pharmaceutical companies.

 General Information
MEDIDATA SOLUTN
-
-, - -
Phone: -
Fax: -
Web: -
Email: None
 
Industry MEDICAL INFO SYS
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 02/12/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 17.78
52 Week High 19.73
52 Week Low 14.53
Beta 0.00
20 Day Moving Average 156,024.55
Target Price Consensus 21.17
 
 % Price Change
4 Week 3.28
12 Week 2.27
YTD 0.00
 % Price Change Relative to S&P 500
4 Week 3.43
12 Week -3.39
YTD 0.00
 Share Information
Shares Outstanding (millions) 0.00
Market Capitalization (millions) 0.00
Short Ratio 0.98
Last Split Date N/A
 Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

 EPS Information
Current Quarter EPS Consensus Estimate 0.07
Current Year EPS Consensus Estimate 0.33
Estimated Long-Term EPS Growth Rate 25.00
Next EPS Report Date 02/12/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 1.67
30 Days Ago 2.00
60 Days Ago 2.00
90 Days Ago 2.00

 Fundamental Ratios
 P/E
Current FY Estimate: 50.80
Trailing 12 Months: -
PEG Ratio 2.03
 EPS Growth
vs. Previous Year -%
vs. Previous Quarter -%
 Sales Growth
vs. Previous Year -%
vs. Previous Quarter: -%
 Price Ratios
Price/Book -
Price/Cash Flow -
Price / Sales -
 ROE
- -
- -
- -
 ROA
- -
- -
- -
 Current Ratio
- -
- -
- -
 Quick Ratio
- -
- -
- -
 Operating Margin
- -
- -
- -
 Net Margin
- -
- -
- -
 Pre-Tax Margin
- -
- -
- -
 Book Value
- -
- -
- -
 Inventory Turnover
- -
- -
- -
 Debt-to-Equity
- -
- -
- -
 Debt to Capital
- -
- -
- -

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research